Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus (Q33374921)

26 July 2017

Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

26 July 2017

0 references

author name string

Chehab G

1

1 reference

26 July 2017

Sander O

2

1 reference

26 July 2017

Fischer-Betz R

3

1 reference

26 July 2017

Schneider M

4

1 reference

26 July 2017

language of work or name

German

0 references

publication date

1 July 2007

1 reference

Zeitschrift fuer Rheumatologie

26 July 2017

1 reference

26 July 2017

66

1 reference

26 July 2017

4

1 reference

26 July 2017

328, 330-6

1 reference

https://scigraph.springernature.com/pub.10.1007/s00393-007-0164-6

26 July 2017

0 references

cites work

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

12 December 2020

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

12 December 2020

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

1 reference

12 December 2020

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

1 reference

12 December 2020

Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of

1 reference

12 December 2020

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

12 December 2020

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice.

1 reference

12 December 2020

The role of B cells in lpr/lpr-induced autoimmunity

1 reference

12 December 2020

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

1 reference

12 December 2020

Criteria for the classification of systemic lupus erythematosus--status 1972.

1 reference

12 December 2020

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

12 December 2020

Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity i

1 reference

12 December 2020

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

1 reference

12 December 2020

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

12 December 2020

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

1 reference

12 December 2020

Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activ

1 reference

12 December 2020

10.1007/S00393-007-0164-6

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference